サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1413998

狭心症治療薬の世界市場レポート 2024年

Angina Pectoris Drugs Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
狭心症治療薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

狭心症治療薬の市場規模は近年力強く成長しています。2023年の118億2,000万米ドルから2024年には124億7,000万米ドルに、CAGR5.5％で拡大します。このような成長は、心血管疾患の蔓延、高齢化社会への人口動態の変化、ライフスタイルの影響、高血圧率の上昇、糖尿病有病率の増加など、いくつかの要因によるものです。

狭心症治療薬の市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR5.6％で154億8,000万米ドルに成長します。予測期間中に予想される成長は、特に世界の肥満率の上昇、精密医療の進歩、予防循環器学の重視の高まり、患者教育に向けた取り組み、革新的な治療手段の継続的な研究など、さまざまな要因の影響を受けています。この予測期間中に予想される主な動向には、遠隔モニタリングのための遠隔医療の利用、実臨床でのエビデンスとアウトカム研究の重要性、患者中心の薬物教育へのシフト、市場アクセスを強化するための戦略的提携の形成、迅速な承認を促進する規制の進歩などが含まれます。

狭心症治療薬市場の成長は、慢性狭心症の有病率の上昇によって促進されると予想されます。慢性狭心症は、心筋への血流低下による胸痛を特徴とし、その治療には重要な薬剤の使用が必要となります。これらの薬剤は、冠動脈性心疾患、心血管疾患、高血圧、肥満と関連することが多いこの症状に罹患している人々に大きな利点を提供します。米国疾病予防管理センターが2023年5月に発表した統計によると、2021年には米国で約375,476人が冠動脈性心疾患で死亡し、これは20歳以上の人口の約5％に相当します。さらに、冠動脈疾患による死亡者10人のうち2人近くが、同年に65歳未満で発生していると推定されました。さらに、2022年12月に国立医学図書館が発表したデータによると、米国では1,000万人以上が狭心症に罹患しており、毎年50万人以上が新たに狭心症と診断されています。その結果、慢性狭心症の有病率の増加は、狭心症治療薬市場の成長を支える重要な要因となっています。

高血圧と糖尿病の急増率は、当面の狭心症治療薬市場の拡大を刺激すると予測されています。高血圧は高い動脈血圧を特徴とし、糖尿病は血糖値の上昇を特徴とする長期的な疾患であり、狭心症などの心血管疾患の一般的な危険因子です。これらの疾患の急増は、狭心症の治療に使われる薬剤の需要を増大させています。例えば、2022年6月の世界保健機関（WHO）のデータでは、2022年4月までに15,000以上の医療施設で250万人以上の高血圧症例が記録されたと報告されています。同様に、2023年6月のオーストラリア保健福祉研究所（Australian Institute of Health and Welfare）からの情報では、糖尿病に罹患したオーストラリア人の数は過去10年間で約2.8倍に急増し、46万人から130万人にエスカレートしていることが強調されています。したがって、高血圧と糖尿病の割合の増加は、狭心症治療薬市場の推進に大きく寄与しています。

2023年の狭心症治療薬市場では、北米が最大地域でした。アジア太平洋は予測期間中に最も急成長する地域と予想されます。狭心症治療薬市場レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の狭心症治療薬市場、薬剤別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 硝酸塩
  • 抗血小板剤
  • ベータアドレナリン遮断薬
  • カルシウムチャネルブロッカー
  • 抗虚血剤
  • スタチン
  • 降圧剤
  • その他
  • 世界の狭心症治療薬市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 安定狭心症
  • 不安定狭心症
  • プリンツメタル狭心症
  • 世界の狭心症治療薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 非経口
  • 経皮
  • その他
  • 世界の狭心症治療薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 病院
  • 在宅ケア
  • 専門クリニック
  • その他

第7章 地域および国の分析

  • 世界の狭心症治療薬市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界の狭心症治療薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 狭心症治療薬市場の競合情勢
  • 狭心症治療薬市場の企業プロファイル
    • Astellas Pharma Inc.
    • Bayer AG
    • Novartis AG
    • AstraZeneca PLC
    • Amgen Inc.

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r11508

“Angina Pectoris Drugs Global Market Report 202 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on angina pectoris drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for angina pectoris drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The angina pectoris drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drugs: Nitrates; Antiplatelet Agents; Beta-adrenergic Blocking Agents; Calcium Channel Blockers; Anti-ischemic Agents; Statins; Antihypertensive Agents; Other Drugs
  • 2) By Indication: Stable Angina; Unstable Angina; Prinzmetal's Angina
  • 3) By Route of Administration: Oral; Parenteral; Transdermal; Other Route Of Administrations
  • 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
  • Companies Mentioned: Astellas Pharma Inc.; Bayer AG; Novartis AG; AstraZeneca PLC; Amgen Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Angina pectoris medications are employed to address the symptoms of angina pectoris, a condition characterized by chest pain or discomfort resulting from inadequate blood and oxygen supply to a portion of the heart. These drugs aim to alleviate the chest pain associated with coronary heart disease.

The primary categories of angina pectoris medications encompass nitrates, antiplatelet agents, beta-adrenergic blockers, calcium channel blockers, anti-ischemic agents, statins, antihypertensive agents, and other pharmaceuticals. Among these, nitrates and nitrites, containing nitrogen and oxygen atoms, play a significant role in managing angina pectoris, a condition marked by chest pain due to reduced blood flow to the heart. Their usage extends to treating stable angina, unstable angina, and Prinzmetal's angina. These medications are delivered through oral, parenteral, transdermal, and various other administration routes utilized in hospitals, homecare settings, specialty clinics, and other end-user contexts.

The angina pectoris drugs market research report is one of a series of new reports from The Business Research Company that provides angina pectoris drugs market statistics, including angina pectoris drugs industry global market size, regional shares, competitors with an angina pectoris drugs market share, detailed angina pectoris drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the angina pectoris drugs industry. This angina pectoris drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The angina pectoris drugs market size has grown strongly in recent years. It will grow from $11.82 billion in 2023 to $12.47 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The rise observed during the historical period can be attributed to several factors, including the widespread occurrence of cardiovascular diseases, demographic shifts toward an aging population, lifestyle-related influences, elevated rates of hypertension, and an increasing prevalence of diabetes.

The angina pectoris drugs market size is expected to see strong growth in the next few years. It will grow to $15.48 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The anticipated growth in the forecast period is influenced by various factors, notably the escalating global rates of obesity, advancements in precision medicine, an increased emphasis on preventive cardiology, initiatives geared towards patient education, and ongoing research into innovative therapeutic avenues. Key trends expected during this forecast period encompass the utilization of telemedicine for remote monitoring, the prominence of real-world evidence and outcome studies, a shift towards patient-centric medication education, the formation of strategic alliances to enhance market access, as well as regulatory advancements facilitating expedited approvals.

The growth of the angina pectoris drug market is anticipated to be fueled by the escalating prevalence of chronic angina pectoris. Chronic angina pectoris, characterized by chest pain due to reduced blood flow to the heart muscle, necessitates the use of crucial medications for its treatment. These drugs offer significant advantages to individuals affected by this condition, which is often associated with coronary heart disease, cardiovascular issues, high blood pressure, and obesity. Statistics from May 2023, provided by the Centers for Disease Control and Prevention, revealed that in 2021, approximately 375,476 people succumbed to coronary heart disease in the United States, equating to around 5% of the population aged 20 and above. Moreover, it was estimated that nearly 2 out of every 10 deaths from coronary artery disease occurred in individuals under the age of 65 in the same year. Additionally, data from the National Library of Medicine in December 2022 indicated that over 10 million individuals in the United States are affected by Angina, with over 500,000 new diagnoses annually. Consequently, the increasing prevalence of chronic angina pectoris is a key driver behind the growth of the angina pectoris drug market.

The burgeoning rates of hypertension and diabetes are projected to stimulate the expansion of the angina pectoris drug market in the foreseeable future. Hypertension, characterized by high arterial blood pressure, and diabetes, a long-term condition marked by elevated blood glucose levels, are common risk factors for cardiovascular ailments such as angina pectoris. The surge in the occurrence of these conditions amplifies the demand for medications used in angina treatment. For instance, data from the World Health Organization in June 2022 reported over 2.5 million recorded cases of hypertension across more than 15,000 healthcare facilities by April 2022. Similarly, information from the Australian Institute of Health and Welfare in June 2023 highlighted that the number of Australians affected by diabetes had surged approximately 2.8 times in the past decade, escalating from 460,000 to 1.3 million individuals. Therefore, the escalating rates of hypertension and diabetes significantly contribute to driving the angina pectoris drug market.

A prominent trend in the angina pectoris drugs market involves a focus on product innovation, with major companies within the industry leveraging new technologies to maintain their market positions. Notably, in March 2023, Hikma Pharmaceuticals plc, a UK-based firm, introduced the Labetalol Hydrochloride Injection, USP, in a prefilled syringe, which received approval from the US Food and Drug Administration (FDA). This particular product, available in hospitals in a 10 mg/2 mL PFS format, serves the purpose of treating severe hypertension and reducing blood pressure.

The key players in the angina pectoris drug market are strategically pursuing approvals for innovative products, such as the FDA's authorization of Nitrostat (Nitroglycerin Sublingual Tablets) for managing angina, aiming to better cater to their existing consumer base. Nitrostat, sanctioned by the FDA for immediate angina treatment or acute prevention, witnessed approval for sale in various strengths (0.3 mg, 0.4 mg, and 0.6 mg) in March 2022, announced by Zydus Lifesciences Ltd., an India-based pharmaceutical company. These sublingual tablets are prescribed for patients with coronary artery disease (CAD) to alleviate angina or chest discomfort, even aiding in preventing soreness before physical activity. Nitroglycerin, a part of the nitrate drug class, functions by dilating and relaxing blood vessels, thus facilitating improved blood circulation to the heart.

In November 2022, Alcon, a US-based pharmaceutical and medical device company, completed the acquisition of Aerie Pharmaceuticals Inc., a move that significantly expands Alcon's commercial product range and development pipeline. Aerie Pharmaceuticals, Inc., a US-based clinical-stage pharmaceutical firm, contributes to the angina pectoris drug market, adding depth and diversity to Alcon's portfolio, particularly in the realm of ophthalmic pharmaceuticals.

Major companies operating in the angina pectoris drugs market report are Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Amgen Inc., Gilead Sciences Inc., Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Otsuka Pharmaceutical Co Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, AbbVie Inc., Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Sanofi SA, Sun BioPharma Inc., Atox Bio Inc., CalciMedica Inc., D-Pharm Ltd., Dynavax Technologies Corporation, Fresenius SE & Co KGaA, Olympus Corporation, SCM Lifescience Co. Ltd., Allergan plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Johnson & Johnson,

North America was the largest region in the angina pectoris drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the angina pectoris drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The angina pectoris drugs market consists of sales of aspirin, ranolazine, and angiotensin-converting enzyme inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Angina Pectoris Drugs Market Characteristics

3. Angina Pectoris Drugs Market Trends And Strategies

4. Angina Pectoris Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Angina Pectoris Drugs Market Size and Growth

  • 5.1. Global Angina Pectoris Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Angina Pectoris Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Angina Pectoris Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Angina Pectoris Drugs Market Segmentation

  • 6.1. Global Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Nitrates
  • Antiplatelet Agents
  • Beta-adrenergic Blocking Agents
  • Calcium Channel Blockers
  • Anti-ischemic Agents
  • Statins
  • Antihypertensive Agents
  • Other Drugs
  • 6.2. Global Angina Pectoris Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Stable Angina
  • Unstable Angina
  • Prinzmetal's Angina
  • 6.3. Global Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • Transdermal
  • Other Route Of Administrations
  • 6.4. Global Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End Users

7. Angina Pectoris Drugs Market Regional And Country Analysis

  • 7.1. Global Angina Pectoris Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Angina Pectoris Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Angina Pectoris Drugs Market

  • 8.1. Asia-Pacific Angina Pectoris Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Angina Pectoris Drugs Market

  • 9.1. China Angina Pectoris Drugs Market Overview
  • 9.2. China Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Angina Pectoris Drugs Market

  • 10.1. India Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Angina Pectoris Drugs Market

  • 11.1. Japan Angina Pectoris Drugs Market Overview
  • 11.2. Japan Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Angina Pectoris Drugs Market

  • 12.1. Australia Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Angina Pectoris Drugs Market

  • 13.1. Indonesia Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Angina Pectoris Drugs Market

  • 14.1. South Korea Angina Pectoris Drugs Market Overview
  • 14.2. South Korea Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Angina Pectoris Drugs Market

  • 15.1. Western Europe Angina Pectoris Drugs Market Overview
  • 15.2. Western Europe Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Angina Pectoris Drugs Market

  • 16.1. UK Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Angina Pectoris Drugs Market

  • 17.1. Germany Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Angina Pectoris Drugs Market

  • 18.1. France Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Angina Pectoris Drugs Market

  • 19.1. Italy Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Angina Pectoris Drugs Market

  • 20.1. Spain Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Angina Pectoris Drugs Market

  • 21.1. Eastern Europe Angina Pectoris Drugs Market Overview
  • 21.2. Eastern Europe Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Angina Pectoris Drugs Market

  • 22.1. Russia Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Angina Pectoris Drugs Market

  • 23.1. North America Angina Pectoris Drugs Market Overview
  • 23.2. North America Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Angina Pectoris Drugs Market

  • 24.1. USA Angina Pectoris Drugs Market Overview
  • 24.2. USA Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Angina Pectoris Drugs Market

  • 25.1. Canada Angina Pectoris Drugs Market Overview
  • 25.2. Canada Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Angina Pectoris Drugs Market

  • 26.1. South America Angina Pectoris Drugs Market Overview
  • 26.2. South America Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Angina Pectoris Drugs Market

  • 27.1. Brazil Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Angina Pectoris Drugs Market

  • 28.1. Middle East Angina Pectoris Drugs Market Overview
  • 28.2. Middle East Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Angina Pectoris Drugs Market

  • 29.1. Africa Angina Pectoris Drugs Market Overview
  • 29.2. Africa Angina Pectoris Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Angina Pectoris Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Angina Pectoris Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Angina Pectoris Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Angina Pectoris Drugs Market Competitive Landscape
  • 30.2. Angina Pectoris Drugs Market Company Profiles
    • 30.2.1. Astellas Pharma Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Bayer AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AstraZeneca PLC
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Amgen Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Angina Pectoris Drugs Market Competitive Benchmarking

32. Global Angina Pectoris Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Angina Pectoris Drugs Market

34. Angina Pectoris Drugs Market Future Outlook and Potential Analysis

  • 34.1 Angina Pectoris Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Angina Pectoris Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Angina Pectoris Drugs Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer